Neutra Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NTRR research report →
Price Chart
About the company
Neutra Corp. specializes in the research, development, and provision of hemp-derived nutraceuticals. Its product portfolio features items such as CBD-infused sports creams, in addition to a variety of other health and wellness goods.
- CEO
- Sydney Jim
- IPO
- 2011
- Employees
- 15
- HQ
- Houston, TX, US
Get TickerSpark's AI analysis on NTRR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $583.58K
- P/E
- 2.00
- PEG
- 0.01
- P/S
- 0.50
- P/B
- -0.46
- EV/EBITDA
- 0.58
- Div Yield
- 0.00%
- Gross Margin
- 76.27%
- Op Margin
- 93.92%
- Net Margin
- 87.15%
- ROE
- -124.55%
- ROIC
- -1801.24%
Latest fiscal year · YoY change
- Revenue
- $1.02M+1403.9%
- Gross Profit
- $656.76K+938.6%
- Op Income
- $87.49K
- Net Income
- $-6,941+93.6%
- EPS
- $0.00+0.0%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.48
- RSI (14)
- 63
- Avg Volume
- 954.86K
No earnings-call transcripts are available for NTRR yet.
- Free Float
- 99.3%
- Shares Outstanding
- 2.92B
- Float Shares
- 2.90B
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 14, 13 | Jim Sydney | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NTRR coverage
Recent articles, reports, and earnings notes.
No research on NTRR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NTRR report →Neutra Corp Targets Expanded Sponsor and CRO Relationships in Q3 & Q4 2026, Reaffirming Full Commitment to Life Sciences Growth
globenewswire.com · Jul 13
Neutra Corp's Subsidiary Neutra Life Sciences Executes New Women's Health Joint Venture and Expands Trial Portfolio
globenewswire.com · Jun 29
Neutra Reflects on 2023 and Looks Forward to 2024
globenewswire.com · Dec 29
Neutra Announces Strategic and Financial Value Creation Plan
globenewswire.com · Oct 30
Latest VIVIS LOI Potential First Step to Phase 1 Clinical Trial on Preventing COVID-19 Infections Using CBD
accesswire.com · Sep 14
Latest VIVIS LOI Potential First Step to Phase 1 Clinical Trial on Preventing COVID-19 Infections Using CBD
accesswire.com · Sep 13
Neutra Corp. Provides Strategic Update
accesswire.com · Aug 16
VIVIS-Brand CBD Products Will Be Available at Festival Foods Flagship Store
accesswire.com · Aug 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.